{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T22:17:07Z","timestamp":1789510627658,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.canrad.2017.09.013","type":"journal-article","created":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T09:09:39Z","timestamp":1523956179000},"page":"236-240","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Trimodalities for bladder cancer in elderly: Transurethral resection, hypofractionated radiotherapy and gemcitabine"],"prefix":"10.1016","volume":"22","author":[{"given":"H.A.H.","family":"Mohamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.S.","family":"Elnaggar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gabr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Abdelrheem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2017.09.013_bib0150","doi-asserted-by":"crossref","first-page":"437971","DOI":"10.1155\/2014\/437971","article-title":"Cancer incidence in Egypt: results of the national population-based cancer registry program","volume":"2014","author":"Ibrahim","year":"2014","journal-title":"J Cancer Epidemiol"},{"key":"10.1016\/j.canrad.2017.09.013_bib0155","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.canep.2009.08.008","article-title":"Incidence analyses of bladder cancer in the Nile delta region of Egypt","volume":"33","author":"Fedewa","year":"2009","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.canrad.2017.09.013_bib0160","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.eururo.2012.11.015","article-title":"Use of potentially curative therapies for muscle-invasive bladder cancer in the united states: results from the national cancer data base","volume":"63","author":"Gray","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.canrad.2017.09.013_bib0165","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.critrevonc.2015.04.006","article-title":"Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: a systematic review of clinical trials","volume":"95","author":"Arcangeli","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.canrad.2017.09.013_bib0170","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0167-8140(97)01943-9","article-title":"Hypofractionated radiotherapy for muscle invasive bladder cancer in the elderly","volume":"43","author":"McLaren","year":"1997","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2017.09.013_bib0175","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1470-2045(13)70386-3","article-title":"The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials","volume":"14","author":"Haviland","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2017.09.013_bib0180","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3389\/fonc.2014.00206","article-title":"Trimodality therapy for bladder preservation in the elderly population with invasive bladder cancer","volume":"4","author":"Turgeon","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.canrad.2017.09.013_bib0185","doi-asserted-by":"crossref","first-page":"952","DOI":"10.6004\/jnccn.2013.0116","article-title":"Trimodality bladder preservation therapy for muscle-invasive bladder cancer","volume":"11","author":"Chen","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.canrad.2017.09.013_bib0190","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","article-title":"Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer","volume":"366","author":"James","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2017.09.013_bib0195","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.radonc.2011.07.026","article-title":"study of radiochemotherapy with gemcitabine in invasive bladder cancer","volume":"102","author":"Borut","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2017.09.013_bib0200","first-page":"41","article-title":"Gemcitabine versus cisplatin in concurrent radio chemotherapy for bladder preservation","volume":"6","author":"Hussin","year":"2016","journal-title":"Cancer Biol"},{"key":"10.1016\/j.canrad.2017.09.013_bib0205","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1200\/JCO.2014.57.5548","article-title":"Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233","volume":"32","author":"Mak","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2017.09.013_bib0210","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC)","volume":"31","author":"Cox","year":"1995","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.canrad.2017.09.013_bib0215","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric Estimation from incomplete observations","volume":"53","author":"Kaplan","year":"2012","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.canrad.2017.09.013_bib0220","first-page":"158","article-title":"Bilharziasis and bladder cancer: a time trend analysis of 9843 patients","volume":"19","author":"Gouda","year":"2007","journal-title":"J Egypt Nat Cancer Inst"},{"key":"10.1016\/j.canrad.2017.09.013_bib0225","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.urolonc.2009.07.020","article-title":"Bladder cancer in the elderly","volume":"27","author":"Shariat","year":"2004","journal-title":"Urol Oncol"},{"key":"10.1016\/j.canrad.2017.09.013_bib0230","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s00345-014-1446-7","article-title":"Postoperative complications and short-term oncological outcomes of patients aged \u226580years undergoing robot-assisted radical cystectomy","volume":"33","author":"Nguyen","year":"2015","journal-title":"World J Urol"},{"key":"10.1016\/j.canrad.2017.09.013_bib0235","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ijrobp.2004.05.074","article-title":"study of conformal radiotherapy with concurrent gemcitabine in locally advanced bladder cancer","volume":"61","author":"Sangar","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2017.09.013_bib0240","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1200\/JCO.2010.31.5721","article-title":"Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer","volume":"29","author":"Choudhury","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2017.09.013_bib0245","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0167-8140(03)00019-7","article-title":"Concomitant boost radiotherapy for muscle invasive bladder cancer","volume":"68","author":"Pos","year":"2003","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2017.09.013_bib0250","first-page":"13","article-title":"Utility of the novel bladder preservation therapy, BOAI-CDDP-radiation (OMC-regimen), for elderly patients with invasive bladder cancer","volume":"38","author":"Azuma","year":"2011","journal-title":"Int J Oncol"},{"key":"10.1016\/j.canrad.2017.09.013_bib0255","doi-asserted-by":"crossref","DOI":"10.4172\/1948-5956.1000205","article-title":"Quality of life in bladder cancer patients treated with radical cystectomy and orthotopic bladder reconstruction versus bladder preservation protocol","volume":"5","author":"El-Sayed","year":"2013","journal-title":"J Cancer Sci Ther"},{"key":"10.1016\/j.canrad.2017.09.013_bib0260","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1200\/JCO.2008.19.5776","article-title":"Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06","volume":"27","author":"Efstathiou","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2017.09.013_bib0265","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0360-3016(00)00430-2","article-title":"A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: results of medical research council trial BA09","volume":"47","author":"Duchesne","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2017.09.013_bib0270","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4236\/jct.2012.31008","article-title":"Organ preservation in bilharzial bladder cancer in Egypt: single institutional experience","volume":"3","author":"Abbas","year":"2012","journal-title":"J Cancer Ther"},{"key":"10.1016\/j.canrad.2017.09.013_bib0275","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000020294","article-title":"Long-term risk of salvage cystectomy after radiotherapy for muscle-invasive bladder cancer","volume":"38","author":"Cooke","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.canrad.2017.09.013_bib0280","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.urology.2003.09.018","article-title":"Concurrent chemoradiotherapy for clinical stage T2 bladder cancer: report of a single institution","volume":"63","author":"Peyromaure","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.canrad.2017.09.013_bib0285","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1590\/S1677-5538.IBJU.2013.01.10","article-title":"Evaluation of acute toxicity and symptoms palliation in a hypofractionated weekly schedule of external radiotherapy for elderly patients with muscular invasive bladder cancer","volume":"39","author":"Kouloulias","year":"2013","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.canrad.2017.09.013_bib0290","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1748-717X-6-75","article-title":"Intensity modulated radiotherapy for elderly bladder cancer patients","volume":"6","author":"Hsieh","year":"2011","journal-title":"Radiat Oncol"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321818300428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321818300428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:27:56Z","timestamp":1761136076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321818300428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S1278321818300428"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2017.09.013","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trimodalities for bladder cancer in elderly: Transurethral resection, hypofractionated radiotherapy and gemcitabine","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2017.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}